290 related articles for article (PubMed ID: 2251873)
1. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines.
Clemens JD; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; van Loon F; Khan MR; Yunis M; Huda S
Vaccine; 1990 Oct; 8(5):469-72. PubMed ID: 2251873
[TBL] [Abstract][Full Text] [Related]
2. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.
Alam MM; Riyadh MA; Fatema K; Rahman MA; Akhtar N; Ahmed T; Chowdhury MI; Chowdhury F; Calderwood SB; Harris JB; Ryan ET; Qadri F
Clin Vaccine Immunol; 2011 May; 18(5):844-50. PubMed ID: 21346055
[TBL] [Abstract][Full Text] [Related]
5. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.
Leung DT; Rahman MA; Mohasin M; Patel SM; Aktar A; Khanam F; Uddin T; Riyadh MA; Saha A; Alam MM; Chowdhury F; Khan AI; Charles R; LaRocque R; Harris JB; Calderwood SB; Qadri F; Ryan ET
Clin Vaccine Immunol; 2012 May; 19(5):690-8. PubMed ID: 22441386
[TBL] [Abstract][Full Text] [Related]
6. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.
Clemens JD; Sack DA; Harris JR; Van Loon F; Chakraborty J; Ahmed F; Rao MR; Khan MR; Yunus M; Huda N
Lancet; 1990 Feb; 335(8684):270-3. PubMed ID: 1967730
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.
Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET
Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016
[TBL] [Abstract][Full Text] [Related]
8. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera.
Clemens JD; van Loon F; Sack DA; Chakraborty J; Rao MR; Ahmed F; Harris JR; Khan MR; Yunus M; Huda S
J Infect Dis; 1991 Jun; 163(6):1235-42. PubMed ID: 2037789
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh.
Sack DA; Clemens JD; Huda S; Harris JR; Khan MR; Chakraborty J; Yunus M; Gomes J; Siddique O; Ahmed F
J Infect Dis; 1991 Aug; 164(2):407-11. PubMed ID: 1856488
[TBL] [Abstract][Full Text] [Related]
10. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.
Jertborn M; Svennerholm AM; Holmgren J
J Clin Microbiol; 1986 Aug; 24(2):203-9. PubMed ID: 3528211
[TBL] [Abstract][Full Text] [Related]
11. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
12. Field trial of oral cholera vaccines in Bangladesh.
Clemens JD; Sack DA; Harris JR; Chakraborty J; Khan MR; Stanton BF; Kay BA; Khan MU; Yunus M; Atkinson W
Lancet; 1986 Jul; 2(8499):124-7. PubMed ID: 2873397
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
[TBL] [Abstract][Full Text] [Related]
14. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
16. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
17. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children.
Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F
Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936
[TBL] [Abstract][Full Text] [Related]
18. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.
Clemens JD; Stanton BF; Chakraborty J; Sack DA; Khan MR; Huda S; Ahmed F; Harris JR; Yunus M; Khan MU
J Infect Dis; 1987 Jan; 155(1):79-85. PubMed ID: 3540139
[TBL] [Abstract][Full Text] [Related]
19. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers.
Pitisuttithum P; Migasena S; Suntharasamai P; Supanaranond W; Desakorn V; Prayurahong B
Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):201-5. PubMed ID: 2609209
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.
Tarique AA; Kalsy A; Arifuzzaman M; Rollins SM; Charles RC; Leung DT; Harris JB; Larocque RC; Sheikh A; Bhuiyan MS; Saksena R; Clements JD; Calderwood SB; Qadri F; Kovác P; Ryan ET
Clin Vaccine Immunol; 2012 Apr; 19(4):594-602. PubMed ID: 22357651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
